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An 86-year-old male patient was attended with dys-
pnoea for 2 weeks, with progressive worsening, dry
cough and decreased appetite. He had a personal
history of prostate cancer diagnosed 2 years before
and dyslipidaemia. He denied smoking history,
exposure to inhaled toxic substances or family
history of chronic lung disease. The patient was
receiving treatment with rosuvastatin 10 mg and
nilutamide 150 mg which was started 1 month
earlier. On physical examination we found the
patient with globally decreased breath sounds and
crackles at the base of the right hemithorax.
Laboratory tests showed no other abnormalities
besides C-reactive protein 69 g/L and slight
hypoxaemia.
The chest X-ray showed bilateral interstitium
inﬁltrates with slight effacement of the costophre-
nic angles and elevation of the right hemicupula
(ﬁgure 1A). The thorax CT scan was consistent
with interstitial pneumonitis (ﬁgure 1B, C).
Serological tests for viral atypical organisms, anti-
nuclear antibodies, ACE inhibitors and antineutro-
phil cytoplasmic antibodies were carried out but
with negative results. Pulmonary function tests,
alveolar lavage and lung biopsy were not per-
formed. The treatment with nilutamide was
discontinued and the patient was started on bron-
chodilator therapy and prednisolone 40 mg/day
with clinical improvement after 3 days of hospital-
isation and discharge from hospital at day 14 with
normal clinical observation, gasimetric normalisa-
tion, negative RCP and improved chest X-ray
imaging. Nilutamide is a non-steroidal antiandro-
gen, which competitively inhibits the binding of
androgens to the androgen receptor.1 Interstitial
pneumonitis is an extremely rare, although
reversible, adverse reaction to non-steroidal antian-
drogen treatment, being described in 1–2% of the
patients taking the drug.2 The mechanisms by
which non-steroidal antiandrogens cause pulmon-
ary disease remain unclear.3
The onset of symptoms was reported 2–8 months
after the beginning of the treatment.2 The prognosis
of drug-induced pneumonitis is relatively good and
can be treated with the withdrawal of the drug with
or without the association of steroids.3
Learning points
▸ Nilutamide is a non-steroidal antiandrogen,
related to bicalutamide and ﬂutamide.
▸ Interstitial pneumonitis is an extremely rare
adverse reaction described in 1–2% of the
patients taking the drug.
▸ The prognosis is relatively good and can be
treated with the withdrawal of the drug with
or without steroid treatment.
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Figure 1 (A) Chest X-ray on admission: Bilateral interstitium inﬁltrates with slight effacement of the costophrenic
angles and elevation of the right hemicupula. (B) Coronal and (C) Cross-section of thorax CT showing accentuation of
interstitium with several parenchymal inﬁltrats, outlining condensation zone in the lower lobe of the right lung, with
thin pleural effusion.
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